|
|
|
Market Research Report
Brands & Strategies: Atypical Antipsychotics
|
Brands & Strategies: Atypical Antipsychotics published by Decision Resources, Inc. in February, 2008. This report consists of 335 Pages and the price starts from US $ 20250.
Abstract
Introduction
The atypical antipsychotics market in the United States, Europe, and Japan,
valued at an estimated $15.9 billion in sales at ex-manufacturer level in
2007, is expected to expand to over $17.8 billion by 2011, before shrinking to
$13.5 billion in 2012. The primary drivers of market growth will be the
addition of new agents, new formulations of currently marketed drugs, and
approvals in new indications such as major depression and generalized anxiety
disorder. However, the launch of generic formulations of risperidone,
olanzapine, quetiapine, ziprasidone, and paliperidone will lead to an overall
decline of the market during the forecast period.
The atypical antipsychotics market has undergone huge shifts in market
leadership that will continue over the forecast period. Eli Lilly' s Zyprexa
has been the U.S. sales leader for many years. However, in 2006, AstraZeneca' s
Seroquel overtook Zyprexa' s leading position in the U.S. market, and Janssen' s
Risperdal overtook Zyprexa' s position as the sales leader for the seven major
markets. Changes in market leadership will continue over the forecast period
as four of the five leading atypicals (Risperdal, Zyprexa, Seroquel, and
Pfizer' s Geodon) face generic competition.
Questions Answered in This Report
- Janssen led the atypical antipsychotics market in 2007, with an estimated
market share of 27.7%, followed closely by AstraZeneca with 25.4% and Eli
Lilly with 24.8%; however, by 2012, Bristol-Myers Squibb/Otsuka
Pharmaceuticals will hold approximately 37.1% of the market. What strategies
will Bristol-Myers Squibb/Otsuka follow to secure a dominant market position
in the atypical antipsychotics market by the end of the forecast period?
- Four of the top five leading atypical antipsychotics--Janssen' s Risperdal,
Eli Lilly' s Zyprexa, AstraZeneca' s Seroquel, and Pfizer' s Geodon-will face
generic erosion before 2012. How will Janssen, Eli Lilly, AstraZeneca, and
Pfizer fare in the market following the patent expiry of their leading brands?
What strategies are these companies employing to face generic erosion and will
they be successful?
- Bristol-Myers Squibb/Otsuka' s Abilify was approved by the FDA for adjunctive
therapy of major depression in November 2007. AstraZeneca' s Seroquel will
likely be approved for major depression and generalized anxiety disorder in
2009. How will the approval of these agents in new indications affect sales of
key competing agents? Which indications will see the greatest growth in
branded atypical sales? How will each indication be affected by the launch of
generics?
- Janssen' s Invega is expected to be the most successful of the emerging
atypical brands, despite slow uptake in the first three months of its launch.
What element of this brand will contribute to its success? How will other
emerging drugs fare in a mature market that includes generics? What brands
will be replaced by these emerging agents?
Scope
Markets Covered: United States, France, Germany, Italy, Spain, United
Kingdom, and Japan.
Competitive Analysis: Detailed discussion of major competitors
including Eli Lilly, Janssen (Johnson & Johnson), AstraZeneca, Bristol-Myers
Squibb, Otsuka Pharmaceutical, and Pfizer; as well as emerging competitors
Wyeth, Solvay Pharmaceuticals, Schering-Plough/Organon, H. Lundbeck, Dainippon
Sumitomo, Vanda, and Forest Laboratories. Included for each competitor is an
analysis of the company' s neuroscience product portfolio, strategic
positioning, and development pipeline in neuroscience. The report features an
indepth discussion of leading brands, sales and market position,
strengths/weaknesses/opportunities/threats (SWOT) analysis, ongoing
postmarketing clinical trials, and strategic initiatives.
Physician Perception of Key Brands: Analysis of physician perceptions
of the atypical antipsychotic market based on a custom survey of 31 U.S.-based
primary care physicians and 31 U.S.-based psychiatrists. The survey is
brand-focused and examines physician perceptions of key competitors, brand
attributes, messaging, and uptake of emerging agents.
Epidemiology: Total prevalent and diagnosed cases for each indication
in each of the major markets are presented for 2007 and 2012. Total
drug-treated cases for each indication in each of the major markets are
presented in an annualized forecast from 2007 to 2012.
Market Forecast: Annualized sales forecasts for branded agents,
including the uptake of new agents, are presented by region, indication,
formulation, and brand from 2007 to 2012.
Table of Contents
Executive Summary
- 2007-2012 Market Dynamics
- Competitive Landscape
- Brand Overview
- Physician Perspectives: Findings of Our Primary Research
Section 1: Introduction
- Scope of the Report
- Survey Methodology
Section 2: Atypical Antipsychotics Market Dynamics
- Atypical Antipsychotics Background
- Prescribers
- Prescriber Trends
- Schizophrenia
- Bipolar Disorder
- Major Depression
- Generalized Anxiety Disorder
- Key Drivers of Prescriber Decisions
- Treatment Dynamics
- Schizophrenia
- Bipolar Disorder
- Major Depression
- Anxiety Disorders
- Usage Patterns for Atypical Antipsychotics
- Key Competing Classes
- Antiepileptics
- Antidepressants
- Lithium
- Benzodiazepines
- Reimbursement Issues
- United States
- Europe
- Japan
- Perceptions of Atypical Antipsychotic Reimbursement
Section 3: Competitive Analysis
- Overview of Competitive Landscape
- Promotional Spending
- Brand-Specific Trends
- Physician Perceptions of Atypical Antipsychotic Brand Promotion
- Comparative Labeling for Key Brands
- Indication Approvals
- Warnings and Side Effects
- Comparative Pricing of Key Brands
- Physician Perceptions
- Perceptions of Competitors in Atypical Antipsychotics
- Perceptions of Brands in Atypical Antipsychotics
- Perceptions of Atypical Antipsychotic Brands by Indication
- Perceptions of Atypical Antipsychotic Brands on Side Effects
- Perceptions of Atypical Antipsychotic Brands on Delivery Attributes
- Perceptions of Atypical Antipsychotic Brands on Clinical Trial Data
- Perceptions of Messaging in Atypical Antipsychotics
Section 4: Established Competitors
- Eli Lilly
- Strategic Overview
- Neuroscience Product Portfolio
- Goals and Vision in Neuroscience
- Current Positioning
- Market Strategy
- Zyprexa
- Current Positioning
- Zyprexa Competitive Analysis
- Key Brand Strategies
- Pricing Strategy
- Messaging
- Lifecycle Management and Strategy in the Atypical Antipsychotics
Market
- Future Positioning and Outlook
- Janssen (Johnson & Johnson)
- Strategic Overview
- Neuroscience Product Portfolio
- Goals and Vision in Neuroscience
- Current Positioning
- Market Strategy
- Pricing Strategy
- Risperdal
- Current Positioning
- Risperdal Competitive Analysis
- Key Brand Strategies
- Lifecycle Management and Strategy in the Atypical Antipsychotics
Market
- Messaging
- Future Positioning and Outlook
- Invega
- Current Positioning
- Invega Competitive Analysis
- Key Brand Strategies
- Current Strategy in the Atypical Antipsychotics Market
- Messaging
- Lifecycle Management and Future Strategy
- Future Positioning and Outlook
- AstraZeneca
- Strategic Overview
- Neuroscience Product Portfolio
- Goals and Vision in Neuroscience
- Current Positioning
- Market Strategy
- Seroquel
- Current Positioning
- Seroquel Competitive Analysis
- Key Brand Strategies
- Pricing Strategy
- Messaging
- Lifecycle Management and Strategy in the Atypical Antipsychotics
Market
- Future Positioning and Outlook
- Bristol-Myers Squibb
- Strategic Overview
- Neuroscience Product Portfolio
- Goals and Vision in Neuroscience
- Current Positioning
- Market Strategy
- Abilify
- Current Positioning
- Abilify Competitive Analysis
- Key Brand Strategies
- Licensing Strategy
- Pricing Strategy
- Messaging
- Lifecycle Management and Strategy in the Atypical Antipsychotics
Market
- Future Positioning and Outlook
- Otsuka Company
- Strategic Overview
- Neuroscience Product Portfolio
- Goals and Vision in Neuroscience
- Abilify
- Pfizer
- Strategic Overview
- Neuroscience Product Portfolio
- Goals and Vision in Neuroscience
- Current Positioning
- Market Strategy
- Geodon
- Current Positioning
- Geodon Competitive Analysis
- Pricing Strategy
- Messaging
- Lifecycle Management and Strategy in the Atypical Antipsychotics
Market
- Future Positioning and Outlook
Section 5: Emerging Competitors
- Physician Perceptions
- Perceptions of Emerging Atypical Antipsychotics
- Schering-Plough/Organon
- Strategic Overview
- Neuroscience Product Portfolio
- Goals and Vision in Neuroscience
- Asenapine
- Development and Commercial Overview
- Competitive Analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Future Positioning and Outlook
- Wyeth
- Strategic Overview
- Neuroscience Product Portfolio
- Goals and Vision in Atypical Antipsychotics
- Bifeprunox
- Development and Commercial Overview
- Competitive Analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Future Positioning and Outlook
- Solvay Pharmaceuticals
- Strategic Overview
- Neuroscience Product Portfolio
- Bifeprunox
- Vanda
- Strategic Overview
- Neuroscience Product Portfolio
- Iloperidone
- Development and Commercial Overview
- Competitive Analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Future Positioning and Outlook
- H. Lundbeck
- Strategic Overview
- Neuroscience Product Portfolio
- Goals and Vision in Atypical Antipsychotics
- Serdolect
- Development and Commercial Overview
- Competitive Analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Future Positioning and Outlook
- Dainippon Sumitomo
- Strategic Overview
- Neuroscience Product Portfolio
- Goals and Vision in Atypical Antipsychotics
- Lonasen
- Development and Commercial Overview
- Future Positioning and Outlook
- Forest Laboratories
- Strategic Overview
- Neuroscience Product Portfolio
- Goals and Vision in Atypical Antipsychotics
- RGH-188
- Development and Commercial Overview
- Future Positioning and Outlook
Section 6: Market Forecast
- Atypical Antipsychotics Market Analysis
- Sales Trends by Region
- Sales Trends by Indication
- Schizophrenia
- Bipolar Disorder
- Major Depression
- Generalized Anxiety Disorder
- Sales Trends by Brand
- Key Patient Populations-Schizophrenia, Bipolar Disorder, Major Depression,
Generalized Anxiety Disorder
- Prevalent Populations of Key Diseases
- Diagnosed Populations of Key Diseases
- Drug-Treated Populations of Key Diseases
Section 7: Appendices
- Acronyms and Abbreviations
- Bibliography
- Methodology
- Epidemiology
- Market Forecast
- Competitive Analysis
- Authors
- About the Authors
- About Decision Resources, Inc.
- For More Information:
Table of Exhibits
Executive Summary
- Exhibit 1: Key Parameters of the Atypical Antipsychotics Market
- Exhibit 2: Atypical Antipsychotics Branded Market, ($MM), Major Markets,
2007-2012
- Exhibit 3: Atypical Antipsychotics Market Competitive Position, 2007 and
2012
- Exhibit 4: Antipsychotics Market, by Company, as a % of Total, 2007 and
2012
- Exhibit 5: Atypical Antipsychotic Brands Market Share, 2007 and 2012
- Exhibit 6: Physician Familiarity with Key Emerging Agents
- Exhibit 7: Surveyed Physicians' Years of Practice
- Exhibit 8: Surveyed Physicians' Patients per Month
- Exhibit 9: Surveyed Physicians' Geographic Distribution
- Exhibit 10: Currently Marketed Atypical Antipsychotic Brands
- Exhibit 11: DSM-IV Diagnostic Criteria for Schizophrenia
- Exhibit 12: Most Influential Factors for Choosing a Specific Atypical
Antipsychotic
- Exhibit 13: Physicians' Preferred Information Sources for Atypical
Antipsychotics
- Exhibit 14: Frequency of Use of Information Sources for Atypical
Antipsychotics
- Exhibit 15: Treatment Algorithm for Schizophrenia
- Exhibit 16: Treatment Algorithm for Bipolar Mania
- Exhibit 17: Treatment Algorithm for Bipolar Depression
- Exhibit 18: Treatment Algorithm for Major Depression
- Exhibit 19: Treatment Algorithm for Anxiety Disorders
- Exhibit 20: Percentage of Branded Antipsychotics' Prescriptions by Brand,
by Indication, and by Region, 2006
- Exhibit 21: Class-Level Patient Share Within Selected Indications, U.S.,
2007
- Exhibit 22: U.S. Formulary Status of Leading Atypical Antipsychotics
- Exhibit 23: Medicaid Formulary Status of Leading Atypical Antipsychotics
- Exhibit 24: Medicare Formulary Status of Leading Atypical Antipsychotics
- Exhibit 25: Physician Perceptions of Zyprexa' s Reimbursement
- Exhibit 26: Physician Perceptions of Risperdal' s Reimbursement
- Exhibit 27: Physician Perceptions of Invega' s Reimbursement
- Exhibit 28: Physician Perceptions of Seroquel' s Reimbursement
- Exhibit 29: Physician Perceptions of Abilify' s Reimbursement
- Exhibit 30: Physician Perceptions of Geodon' s Reimbursement
- Exhibit 31: Atypical Antipsychotics Sales ($MM), by Country, 2007
- Exhibit 32: Atypical Antipsychotics Market Competitive Position, 2007 and
2012
- Exhibit 33: Atypical Antipsychotics Major-Market Sales ($MM), by Brand,
2007-2012
- Exhibit 34: Promotional Spend for Atypical Antipsychotics Therapies, by
Company, 2006
- Exhibit 35: Promotional Spend, by Competitor, as a % of Total Promotional
Spend for Atypical Antipsychotics, 2004-2006
- Exhibit 36: Promotional Spend for Atypical Antipsychotics, by Brand, 2006
- Exhibit 37: Physician Perception of the Atypical Antipsychotic with the
Most Promotional Material
- Exhibit 38: Physician Perception of the Atypical Antipsychotic with the
Most Patient Requests
- Exhibit 39: Physician Perception of the Most Important Channel
Schizophrenic Patients Use to Learn About Atypical Antipsychotics
- Exhibit 40: Physician Perception of the Most Important Channel Bipolar
Patients Use to Learn About Atypical Antipsychotics
- Exhibit 41: Physician Perception of the Most Important Channel Major
Depression Patients Use to Learn About Atypical Antipsychotics
- Exhibit 42: Physician Perception of the Most Important Channel Generalized
Anxiety Disorder Patients Use to Learn About Atypical Antipsychotics
- Exhibit 43: Labeled Indications for Key Brands, 2007
- Exhibit 44: Labeled Warnings Comparison for Key Brands, 2007
- Exhibit 45: Price per Day ($), Key Brands, Schizophrenia, 2006
- Exhibit 46: Price per Day ($), Key Brands, Bipolar Disorder, 2006
- Exhibit 47: Price per Day ($), Key Brands, Major Depression, 2006
- Exhibit 48: Price per Day ($), Key Brands, Generalized Anxiety Disorder,
2006
- Exhibit 49: Physician Top-of-Mind Mentions for Atypical Antipsychotics
Pharmaceutical Companies
- Exhibit 50: Physician Perception of the Reputations of Atypical
Antipsychotics Competitors
- Exhibit 51: Factors Impacting Physician Perception of Competitors in the
Atypical Antipsychotics Market
- Exhibit 52: Physician Rankings of "Best" Companies in the Atypical
Antipsychotics Market
- Exhibit 53: Physician Rankings of Competitors, by Attributes
- Exhibit 54: Physician Familiarity with Atypical Antipsychotic Brands
- Exhibit 55: Physician Top-of-Mind Mentions for Atypical Antipsychotic
Brands in the Treatment of Schizophrenia
- Exhibit 56: Physician Top-of-Mind Mentions for Atypical Antipsychotic
Brands in the Treatment of Bipolar Disorder
- Exhibit 57: Physician Top-of-Mind Mentions for Atypical Antipsychotic
Brands in the Treatment of Major Depression
- Exhibit 58: Physician Top-of-Mind Mentions for Atypical Antipsychotic
Brands in the Treatment of Generalized Anxiety Disorder
- Exhibit 59: Physician Perceptions of Whether Weight Gain/Metabolic Side
Effects Are an Advantage, by Brand
- Exhibit 60: Physician Perceptions of Whether EPS or Other Movement Side
Effects Are an Advantage, by Brand
- Exhibit 61: Physician Perceptions of Whether Cardiovascular Side Effects
Are an Advantage, by Brand
- Exhibit 62: Physician Perceptions of Whether Compliance Is an Advantage,
by Brand
- Exhibit 63: Physician Perceptions of Whether Cost Is an Advantage, by Brand
- Exhibit 64: Physician Perceptions of Whether the Weight of Evidence from
Clinical Trials Is an Advantage, by Brand
- Exhibit 65: Physician Perceptions of Whether the Amount of Available Drug
Data in Other Indications Is an Advantage, by Brand
- Exhibit 66: Physician Perceptions of the Atypical Antipsychotic That
Benefited the Most Based on Publication of Results from CATIE Trials
- Exhibit 67: Physician Response to Marketing Messages for a Hypothetical
Atypical Antipsychotic Brand
- Exhibit 68: Physician Perception of Core Marketing Messages for Atypical
Antipsychotics
- Exhibit 69: Physician Perception of Most Influential Branded-Drug
Messaging in the Atypical Antipsychotics Market
- Exhibit 70: Physician Identification of Slogans to the Correct Atypical
Antipsychotic Brands
- Exhibit 71: Summary of Eli Lilly' s Neuroscience Product Portfolio
- Exhibit 72: Physician Perceptions of Zyprexa' s Efficacy
- Exhibit 73: Physician Perceptions of Zyprexa' s Drug Attributes
- Exhibit 74: Drug Prescriptions to Be Replaced by Zyprexa Adhera if It
Becomes Commercially Available
- Exhibit 75: Ongoing Eli Lilly-Sponsored Phase III and IV Clinical Trials
for Zyprexa
- Exhibit 76: Ongoing Phase III and IV Clinical Trials for Zyprexa Adhera
- Exhibit 77: Zyprexa Sales by Formulation ($MM), 2007-2012
- Exhibit 78: Zyprexa Sales by Region ($MM), 2007-2012
- Exhibit 79: Zyprexa Sales ($MM) and Market Share, by Country, 2007-2012
- Exhibit 80: Summary of Johnson & Johnson' s Central Nervous System Product
Portfolio
- Exhibit 81: Physician Perceptions of Risperdal' s Efficacy
- Exhibit 82: Physician Perceptions of Risperdal' s Drug Attributes
- Exhibit 83: Ongoing Johnson & Johnson-Sponsored Phase III and IV Clinical
Trials for Risperdal
- Exhibit 84: Ongoing Phase III and IV Clinical Trials for Risperdal Consta
- Exhibit 85: Risperdal Sales by Formulation ($MM), 2007-2012
- Exhibit 86: Risperdal Sales by Region ($MM), 2007-2012
- Exhibit 87: Risperdal Sales ($MM) and Market Share, by Country, 2007-2012
- Exhibit 88: Physician Perceptions of Invega' s Efficacy
- Exhibit 89: Physician Perceptions of Invega' s Drug Attributes
- Exhibit 90: Drug Prescriptions to Be Replaced by Paliperidone Palmitate
(Depot) if It Becomes Commercially Available
- Exhibit 91: Ongoing Johnson & Johnson-Sponsored Phase III and IV Clinical
Trials for Invega
- Exhibit 92: Ongoing Johnson & Johnson-Sponsored Phase III and IV Clinical
Trials for Paliperidone Palmitate
- Exhibit 93: Invega Sales by Formulation ($MM), 2007-2012
- Exhibit 94: Invega Sales by Region ($MM), 2007-2012
- Exhibit 95: Invega Sales ($MM) and Market Share, by Country, 2007-2012
- Exhibit 96: Summary of AstraZeneca' s Neuroscience Product Portfolio
- Exhibit 97: Physician Perceptions of Seroquel' s Efficacy
- Exhibit 98: Physician Perceptions of Seroquel' s Drug Attributes
- Exhibit 99: Drug Prescriptions to be Replaced by Seroquel XR
- Exhibit 100: Ongoing AstraZeneca-Sponsored Phase III and IV Clinical
Trials for Seroquel
- Exhibit 101: Ongoing AstraZeneca-Sponsored Phase III and IV Clinical
Trials for Seroquel XR
- Exhibit 102: Seroquel Sales, by Region ($MM), 2007-2012
- Exhibit 103: Seroquel Sales ($MM) and Market Share, by Country, 2007-2012
- Exhibit 104: Summary of Bristol-Myers Squibb' s Neuroscience Product
Portfolio
- Exhibit 105: Physician Perceptions of Abilify' s Efficacy
- Exhibit 106: Physician Perceptions of Abilify' s Drug Attributes
- Exhibit 107: Ongoing Bristol-Myers Squibb-Sponsored Phase III and IV
Clinical Trials for Abilify
- Exhibit 108: Ongoing Otsuka-Sponsored Phase III and IV Clinical Trials for
Abilify
- Exhibit 109: Ongoing Bristol-Myers Squibb Academic-Sponsored Phase III and
IV Clinical Trials for Abilify
- Exhibit 110: Abilify Sales by Formulation ($MM), 2007-2012
- Exhibit 111: Abilify Sales by Region ($MM), 2007-2012
- Exhibit 112: Abilify Sales ($MM) and Market Share, by Country, 2007-2012
- Exhibit 113: Summary of Otsuka' s Neuroscience Product Portfolio
- Exhibit 114: Summary of Pfizer' s Neuroscience Product Portfolio
- Exhibit 115: Physician Perceptions of Geodon' s Efficacy
- Exhibit 116: Physician Perceptions of Geodon' s Drug Attributes
- Exhibit 117: Ongoing Pfizer- Sponsored Phase III and IV Clinical Trials
for Geodon
- Exhibit 118: Ongoing Pfizer Academic-Sponsored Phase III and IV Clinical
Trials for Geodon
- Exhibit 119: Geodon Sales by Formulation ($MM), 2007-2012
- Exhibit 120: Geodon Sales by Region ($MM), 2007-2012
- Exhibit 121: Geodon Sales ($MM) and Market Share, by Country, 2007-2012
- Exhibit 122: Physician Familiarity with Antipsychotics in Late-Stage
Development
- Exhibit 123: Physician Ranking of Emerging Antipsychotics
- Exhibit 124: Factors Prior to Launch Affecting Physicians' Willingness to
Prescribe Emerging Antipsychotics
- Exhibit 125: Summary of Organon' s Neuroscience Product Portfolio
- Exhibit 126: Summary of Schering-Plough' s Neuroscience Product Portfolio
- Exhibit 127: Drug Prescriptions to Be Replaced by Asenapine if It Becomes
Commercially Available
- Exhibit 128: Asenapine Sales by Region ($MM), 2007-2012
- Exhibit 129: Expected Asenapine Sales ($MM) and Market Share, by Country,
2007-2012
- Exhibit 130: Summary of Wyeth' s Neuroscience Product Portfolio
- Exhibit 131: Drug Prescriptions to Be Replaced by Bifeprunox if It Becomes
Commercially Available
- Exhibit 132: Bifeprunox Sales by Region ($MM), 2007-2012
- Exhibit 133: Expected Bifeprunox Sales ($MM) and Market Share, by Country,
2007-2012
- Exhibit 134: Summary of Solvay' s Neuroscience Product Portfolio
- Exhibit 135: Drug Prescriptions to Be Replaced by Iloperidone if It
Becomes Commercially Available
- Exhibit 136: Iloperidone Sales ($MM), 2007-2012
- Exhibit 137: Expected Iloperidone Sales ($MM) and Market Share, by
Country, 2007-2012
- Exhibit 138: Serdolect Sales ($MM), 2007-2012
- Exhibit 139: Expected Serdolect Sales ($MM) and Market Share, by Country,
2007-2012
- Exhibit 140: Summary of Dainippon Sumitomo' s Neuroscience Product Portfolio
- Exhibit 141: Lonasen Sales ($MM), 2007-2012
- Exhibit 142: Expected Lonasen Sales ($MM) and Market Share, by Country,
2007-2012
- Exhibit 143: Physician Willingness to Prescribe a Generic Antipsychotic in
the First Year of Its Availability
- Exhibit 144: Atypical Antipsychotics Market ($MM), Major Markets, 2007-2012
- Exhibit 145: Atypical Antipsychotics Market ($MM), Major Markets,
2007-2012 by Region
- Exhibit 146: Timeline of Key Events, Atypical Antipsychotics Market,
2007-2012
- Exhibit 147: Key Launch Events, Atypical Antipsychotics Market, 2007-2012
- Exhibit 148: Expected Generic Entries, Atypical Antipsychotics Market,
2007-2012
- Exhibit 149: Physician Perception of the Impact of Future Events in the
Atypical Antipsychotics Market
- Exhibit 150: Atypical Antipsychotics Market ($MM), by Country (Graphical
Format), 2007-2012
- Exhibit 151: Atypical Antipsychotics Market ($MM), by Country (Tabular
Format), 2007-2012
- Exhibit 152: Key Atypical Antipsychotic Brands, by Indication, as a % of
Total, 2007 and 2012
- Exhibit 153: Zyprexa Franchise, by Indication, as a % of Total, 2007 and
2012
- Exhibit 154: Risperdal Franchise, by Indication, as a % of Total, 2007 and
2012
- Exhibit 155: Seroquel Franchise, by Indication, as a % of Total, 2007 and
2012
- Exhibit 156: Abilify Franchise, by Indication, as a % of Total, 2007 and
2012
- Exhibit 157: Geodon Franchise, by Indication, as a % of Total, 2007 and
2012
- Exhibit 158: Atypical Antipsychotics Market ($MM), by Brand (Graphical
Format), 2007-2012
- Exhibit 159: Atypical Antipsychotics Market ($MM), by Brand (Tabular
Format), 2007-2012
- Exhibit 160: Prevalent Populations of Key Diseases in the Atypical
Antipsychotics Market, Major Markets, 2007 and 2012
- Exhibit 161: Diagnosed Populations of Key Diseases in the Atypical
Antipsychotics Market, Major Markets, 2007 and 2012
- Exhibit 162: Drug-Treated Populations of Key Diseases in the Atypical
Antipsychotics Market, Major Markets, 2007 and 2012
- Exhibit 163: Drug-Treated Populations for Key Diseases in the Atypical
Antipsychotics Market, by Region, 2007 and 2012
- Exhibit 164: Drug-Treated Populations for Key Diseases in the Atypical
Antipsychotics Market, by Region, 2007-2012
|
 |
